NasdaqGS:ASNDBiotechs
A Look At Ascendis Pharma (ASND) Valuation After Key TransCon Trial Successes And Yuviwel FDA Approval
Ascendis Pharma (NasdaqGS:ASND) has drawn fresh attention after positive Week 52 Phase 2 New InsiGHTS data for TransCon hGH in Turner syndrome and long term ApproaCH trial results for TransCon CNP in achondroplasia.
On top of these trial updates, accelerated FDA approval for Yuviwel, the TransCon CNP treatment for achondroplasia, adds a new regulatory milestone that many investors are now weighing against Ascendis Pharma’s recent share performance.
See our latest analysis for Ascendis...